Day Trading Reports
  • Business
  • World News
  • Politics
  • Investing
  • Business
  • World News
  • Politics
  • Investing

Day Trading Reports

Investing

Lobe Sciences Ltd. to Attend the ArcStone-Kingswood Growth Summit 2025 in Toronto

by admin September 16, 2025
September 16, 2025
Lobe Sciences Ltd. to Attend the ArcStone-Kingswood Growth Summit 2025 in Toronto

lobe sciences ltd. (CSE: LOBE,OTC:LOBEF) (OTCQB: LOBEF) (FSE: LOBE.F) (‘Lobe Sciences’ or the ‘Company’) a clinical stage biopharmaceutical company focused on developing products to treat diseases with significant unmet medical needs is pleased to announce its participation in the upcoming ArcStone-Kingswood Growth Summit in Toronto, taking place at the St. Regis Toronto on September 18, 2025. Dr. Frederick D Sancilio, CEO of lobe sciences ltd. will be presenting the company’s recent milestones and future growth strategy.

The ArcStone-Kingswood Growth Summit will be hosting over 20 companies and a curated group of investors for a full day of pre-arranged, targeted 1-on-1 meetings, panel discussions and networking opportunities.

Alongside the schedule of pre-booked meetings matching investors with appropriate projects, the conference program will provide amble opportunities to mix and mingle with the industry professionals and catch up on key industry developments.

Interested investors who would like to attend the ArcStone-Kingswood Growth Summit can register to request for a free invitation here.

About ArcStone Securities and Investments Corp.

ArcStone Securities and Investments Corp. is a diversified financial services firm with offices in Toronto and New York. Our firm specializes in providing bespoke solutions to mid-market companies worldwide, with a particular focus on cross-border transactions between Canada and the United States. Our partnership with Kingswood US enhances our ability to offer a full spectrum of financial services to our clients.

About Kingswood US

Kingswood US is a mid-market investment bank with a strong retail equity capital markets franchise and deep-rooted investment bank. The firm is dedicated to providing comprehensive financial services, including investment banking, wealth management, and capital raising, to clients across the United States.

About lobe sciences ltd.

Lobe Sciences Ltd. is a clinical stage biopharmaceutical company focused on developing novel therapies for rare neurological and hematological conditions. The company operates through two subsidiaries:

  • Altemia, Inc. is addressing sickle cell disease with two complementary assets: a medical food currently in early-stage distribution, and S-100, a patent-pending therapeutic candidate designed to treat the underlying pathology of the disease.

Lobe’s pipeline is differentiated by intellectual property, clinical momentum, and a strategic focus on high-value, underserved markets.

For additional Information, please contact:

lobe sciences ltd.
info@lobesciences.com
www.lobesciences.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/265683

News Provided by Newsfile via QuoteMedia

This post appeared first on investingnews.com

previous post
Angkor Resources: Unlocking Cambodia’s Resource Potential through Energy and Minerals Assets
next post
Crypto Market Update: Bitcoin ETF Inflows Hit US$2.3 Billion as Traders Bet on Fed Easing

Related Posts

SAGA Metals Completes Strategic Infrastructure Upgrades in Preparation...

July 31, 2025

Gold’s Meteoric Rise: Can the Price Break US$4,000...

October 2, 2025

Altech Batteries LimitedAcquisition of Additional Investments CERENERGY and...

February 28, 2025

Crypto Market Update: Stablecoins Top US$283 Billion in...

August 31, 2025

Keith Weiner: All Roads Lead to Gold Right...

March 27, 2025

Editor’s Picks: Gold Tariff Threat Ends, Price Reacts...

August 16, 2025

Silo Wellness Submits CSE Listing Statement for Review...

September 29, 2025

Cartier Resources Announces Subscription Agreement for Flow-Through Units...

April 2, 2025

Grant Williams: Market Turbulence Ahead, but Resource Space...

January 30, 2025

Graphite Market Update: H1 2025 in Review

August 19, 2025

    Become a VIP member by signing up for our newsletter. Enjoy exclusive content, early access to sales, and special offers just for you! As a VIP, you'll receive personalized updates, loyalty rewards, and invitations to private events. Elevate your experience and join our exclusive community today!


    By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.

    Editors’ Picks

    • 1

      Forum Energy Metals and Global Uranium Announce Exploration Update on Drill Targeting, Northwest Athabasca Project, Saskatchewan

      January 31, 2025
    • 2

      Mega M&A: Rio Tinto-Glencore Merger Sparks Chatter

      January 28, 2025
    • 3

      Excellent 90% recoveries at Cork Tree Well & Board Update

      February 17, 2025
    • 4

      Netflix shares soar as company reports surging revenue, tops 300 million subscribers

      January 23, 2025
    • 5

      Financial Agreement signed releasing $2M grant

      January 23, 2025
    • 6

      Cyclopharm Signs US Agreement with HCA Healthcare for Technegas®

      January 23, 2025
    • 7

      FDA officially authorizes Zyn nicotine pouches for sale following health review

      January 23, 2025
    • About us
    • Contacts
    • Privacy Policy
    • Terms & Conditions

    Disclaimer: daytradingreports.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.


    Copyright © 2025 daytradingreports.com | All Rights Reserved